Management of chronic liver disease.
Childhood liver disorders have, in general, mode of presentations which are distinct from that in adult population. It is due to varying etiology and natural history of the liver diseases in childhood. Chronic hepatitis B and C can be managed with alpha interferon. Remission rates in children have been reported to be between 20-58%. Recently available lamuvidine has also been used in combination with interferon therapy. Oral chelation therapy and liver transplantation have radically affected the outcome of patients with Wilson's disease. Corticosteroids and immunosuppressive therapy are effective in reducing both morbidity and mortality due to auto-immune hepatitis. Offending carbohydrates are eliminated from the diet of patients with galactosemia and hereditary fructose intolerance. The most important and often neglected component of management of chronic liver diseases in childhood are nutritional management and prompt interventions for ascites, spontaneous bacterial peritonitis, portal hypertension and hepatic encephalopathy. With definitive etiological and histological assessment and institution of specific as well as supportive therapy, children with chronic liver disease can have a prolonged survival with improved quality of life. Several of them can potentially receive the liver transplant as and when it becomes available.
Thapa
B R
BR
Division of Pediatric Gastroenterology & Nutrition, Postgraduate Institute of Medical Education & Research, Chandigarh.
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D005260:Female; D019694:Hepatitis B, Chronic / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D006527:Hepatolenticular Degeneration / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D006801:Humans; D007194:India; D008107:Liver Diseases / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery*; D016031:Liver Transplantation; D008297:Male; D011379:Prognosis; D018570:Risk Assessment; D015996:Survival Rate; D016896:Treatment Outcome